Abstract
Overview
Introduction
The global anxiety disorders market is set to decline from $4.5 billion in
2006 to $2.6 billion by 2015 (CAGR 2006-15 -6.0%). This will be primarily due
to the launch of numerous generic anxiety drugs from 2006 onwards, which will
offset the revenue growth derived from existing drugs seeking additional
anxiety indications, and the launch of several novel anxiety drugs.
Scope
- Detailed pipeline analysis for key products in development for GAD, SAD,
OCD, PTSD, PMDD and panic disorder, plus drug sales forecasts to 2015
- Overview of patient potential segmentation by indication and unmet needs
in anxiety disorders across the US, Japan, France, Germany, Italy, Spain & UK
- Benchmarking of key clinical and company attractiveness of late-phase
pipeline products
- Detailed clinical trial information and opinions from key thought leaders
Report Highlights
To maximize drug revenues as a final step before generic incursion, a number
of existing market players are seeking approvals in additional anxiety
indications. However, sales of $1.6 billion in 2006 will decline over the
long-term to $1.2 billion in 2015.
Manufacturers with existing branded CNS drugs already approved for indications
other than anxiety, are also seeking secondary indications in the anxiety
market. Datamonitor forecasts that these drugs will enter the anxiety market
from 2007 onwards, and will reach peak anxiety specific revenues of $413m in
2013.
Several novel anxiety drugs will be launched over the forecast period from
2006 onwards, including Predix's PRX-00023 (oral non-azapirone 5-HT1A agonist)
in Phase III for GAD, and Schering AG/Berlex's YAZ (low dose
drospirenone/ethinyl estradiol) and Wyeth's Librel (low dose
levonorgestrel/ethinyl estradiol), both in development for PMDD.
Reasons to Purchase
- Understand unmet needs in the anxiety market based on key opinion leader
comments regarding both currently marketed and pipeline products
- Benchmark key late-stage anxiety compounds against current market leaders
- Assess the global sales forecasts of late-stage pipeline drugs for anxiety
and examine their clinical and commercial potential
View Cart
